Lung Cancer News

The FDA Oncologic Drugs Advisory Committee on Thursday voted against questions regarding the benefits vs. risks of two cancer treatments for which new drug applications have been filed.

The FDA granted regular approval to selpercatinib for treatment of certain patients with non-small cell lung cancer.

Sotorasib significantly extended PFS compared with standard-of-care docetaxel as second-line therapy for patients with KRASG12C-mutated non-small cell lung cancer, data from the randomized phase 3 CodeBreak 200 trial showed.

Exposure to increased concentrations of airborne particulate matter appeared associated with increased risk for EGFR-mutated non-small cell lung cancer among never-smokers, according to study results presented at ESMO Congress.

Immediate provision of an intensive telephone-based smoking cessation intervention was associated with increased rates of smoking cessation at 3 months, researchers reported at the European Respiratory Society International Congress.

Sotorasib prolonged PFS compared with standard chemotherapy for certain patients with non-small cell lung cancer, according to topline data released by the agent’s manufacturer.

U.S. health care spending on respiratory conditions, especially chronic conditions like asthma and COPD, increased dramatically from 1996 to 2016, researchers reported in the American Journal of Respiratory and Critical Care Medicine.

Informed consent forms for interventional oncology clinical trials are often lengthy and written at too high of a reading level for some patients, making it hard for them to weigh the decision to participate, according to study results.

Younger adults with lung cancer had a higher likelihood of having late-stage disease at diagnosis than older adults, according to study results.

About 15% of a large cohort of patients with lung cancer had pathogenic germline variants, nearly all of which could be clinically actionable, according to study results presented during an ASCO Plenary Series session.